Skip to main content
SpringerLink
Log in

Medications

  • Chapter
Facilitating Pathways

  • 181 Accesses

Abstract

Psychotropics are a necessary, albeit not sufficient part of the therapeutic approach to child and adolescent psychiatric illnesses. Indeed, there are few, if any, psychiatric disorders that have their onset in this age group for which medications should not be considered - either as a primary treatment for the syndrome or as a treatment for specific symptoms associated with the syndrome. In other words, medication treatment may be directed towards ameliorating the disorder itself (as in the case of antidepressant treatment of major depressive disorder) or may be directed towards the improvement of specific symptoms known to be sensitive to medication effects, while not directly treating the psychiatric illness per se (for example, aggressive outbursts in autism).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  • Am Acad Child Adolesc Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with schizohprenia. J Am Acad Child Adolesc Psychiatry. 40:45–235, 2001.

    Google Scholar 

  • Biederman J, Mick E, Spencer T, et al. Therapeutic dilemmas in the pharmacotherapy of bipolar depression in the young. J Child Adolesc Psychopharmacol. 10:185–192, 2000.

    Article  CAS  PubMed  Google Scholar 

  • Brooks S, Krulewicz S, Kutcher S. The Kutcher Adolescent Depression Scale: assessment of its evaluative properties over the course of an eight week pediatric pharmacotherapy trial. J Child Adolesc Psychopharmacol. 13:337–349, 2003.

    Article  PubMed  Google Scholar 

  • Bryden K, Carrey N, Kutcher S. Update and recommendations for the use of antipsychotics in early-onset psychosis. J Child Adolesc Psychopharmacology. 11:113–130, 2001.

    Article  CAS  Google Scholar 

  • Carlson, G. Clinical aspects of child and adolescent psychopharmacology. In S. Kutcher ed. Practical Child and Adolescent Psychopharmacology. Cambridge University Press, Cambridge, pp 70–90, 2002.

    Chapter  Google Scholar 

  • Carrey N. Developmental neurobiology: implications for pediatric psychopharmacology. Can J Psychiatry. 46:810–818, 2001.

    CAS  PubMed  Google Scholar 

  • Carrey N, Kutcher S. Developmental pharmacodynamics: implications for child and adolescent psychopharmacology. J Psychiatry Neurosci. 23:274:276, 1998.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Findling R. The future of pharmacotherapy for pediatric anxiety. Expert Opin Pharmacother. 3:574–574, 2002.

    Article  Google Scholar 

  • Findling R, McNamara N, Youngstrom E, et al. A prospective, open-label trial ofolanzapine in adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 42:170–175, 2003.

    Article  PubMed  Google Scholar 

  • Gillberg C. Typical neuroleptics in child and adolescent psychiatry. Eur Child Adolesc Psychiatr. 9: Suppl. 1:12–18, 2000.

    Google Scholar 

  • Glenberg A. SSRIs for children. Biological Therapies in Psychiatry. 26:1, 2003.

    Google Scholar 

  • Greenhill L, Pliszka S, Dulcan M, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents and adults. J Am Acad Child Adoles Psychiatry. 41:265–495, 2002.

    Google Scholar 

  • Greenhill L, Vitiello B, Abikoff H, et al. Developing methodologies for monitoring long-term safety of psychotropic medications in children: apart on the NINH conference, Sept. 25, 2000. J. Am Acad Child Adolesc Psychiatry. 42: 651–655, 2003.

    Article  PubMed  Google Scholar 

  • Guerrero A. General medical considerations in child and adolescent patients who present with psychiatric symptoms. Child Adolesc. Psychiatr Clin N Am, 12:613–628, 2003.

    Article  PubMed  Google Scholar 

  • Kastelic E, Labellarte M, Ridde M. Selective serotonin reuptake inhibitors for children and adolescents. Curr Psychiatry Rep. 2:117–123, 2000.

    Article  CAS  PubMed  Google Scholar 

  • Koplewicz H., Green W. eds. J of Child and Adolescent Psychopharmacology. Mary Ann Liebert Inc., New York, 1999.

    Google Scholar 

  • Kowatch R, Sethuramen G, Hume J, et al. Combination pharmacotherapy in children and adolescents with bipolar disorder. Biol Psychiatry. 53: 978–984, 2003.

    Article  CAS  PubMed  Google Scholar 

  • Kusumakar V, MacMaster F, Kutcher S, Shulman K. Bipolar disorder in young people, the elderly and pregnant women. In Yatham L, Kusumakar V, Kutcher S eds. Bipolar Disorder: A Clinician’s Guide to Biological Treatments. Brunner-Routledge, New York, 2002. pp 85–114.

    Google Scholar 

  • Kutcher S. ed. Child and Adolescent Psychopharmacology News. Guilford Press, New York, 1999.

    Google Scholar 

  • Kutcher S. Child and Adolescent Psychopharmacology. W.B. Saunders, New York, 1997.

    Google Scholar 

  • Kutcher S. Adolescent onset bipolar illness. In A. Marneros and Jules Agnst eds. Bipolar Disorders: 100 Years After Manic-Depressive Insanity. Kulwer Academic Publishers, Dordrecht, Netherlands, 2000, pp 139–152.

    Google Scholar 

  • Kutcher S. Practical clinical issues regarding child and adolescent psychopharmacology. Child Adolesc Psychiatr Clin N Am. 9:245–260, 2000.

    CAS  PubMed  Google Scholar 

  • Kutcher S ed. Practical Child and Adolescent Psychopharmacology, Cambridge U. Press, Cambridge, 2002.

    Google Scholar 

  • Kutcher S, Aman M, Brooks S, et al. International consensus statement on attention-deficit/hyperactivity disorder ADHD and disruptive behavior disorders DBD’s: Clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol. 14:11–28, 2004.

    Article  CAS  PubMed  Google Scholar 

  • Labellarte M, Ginsburg G, Walkup J, et al. The treatment of anxiety disorders in children and adolescents. Biol Psychiatry. 46:1567–1578, 1999.

    Article  CAS  PubMed  Google Scholar 

  • Licht R, Vestergaard P, Kessing G, et al. Psychopharmacological treatment with lithium and anti-epileptic drugs: suggested guidelines from the Danish Psychiatric Association and the Child and Adolescent Psychiatric Association in Denmark. Acta Psychiatr Scan Suppl. 419:1–22, 2003.

    Article  CAS  Google Scholar 

  • March J, Vitiello B. Advances in pediatric neuropsychopharmacology: an overview. Int J Neuropsychopharmacol. 4:141–147, 2001.

    Article  CAS  PubMed  Google Scholar 

  • Markowitz J, Straughn A, Patrick N. Advances in the pharmacotherapy of attention-deficit hyperactivity disorder: focus on methylphenidate formulations. Pharmacotherapy. 23:1281–1299, 2003.

    Article  CAS  PubMed  Google Scholar 

  • Martin A, Kaufman J, Charney D. Pharmacotherapy of early-onset depression: Update and new directions. Child Adolesc Psychiatr Clin N Am. 9:135–157, 2000.

    CAS  PubMed  Google Scholar 

  • McClellan J, Werry J. Evidence-based treatments in child and adolescent Psychiatry: an inventory. J. Amer Acad Child and Adolesc Psychiatry. 43:1388–1400, 2003.

    Article  Google Scholar 

  • McCracken J, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J. Med. 347:314–321, 2002.

    Article  CAS  PubMed  Google Scholar 

  • Mitka M. FDA alert on anti-depressants for youth. JAMA. 290:2534, 2003.

    Article  PubMed  Google Scholar 

  • Nobile M, Cataldo G, Marino C. Diagnosis and treatment of dysthymia in children and adolescents. CNS Drugs. 17: 927–946, 2003.

    Article  PubMed  Google Scholar 

  • Olfson M. et al. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry. 60:978–982, 2003.

    Article  PubMed  Google Scholar 

  • Osterheld J. A review of developmental aspects of cytochrome P450. J of Child and AdolescPsychopharmacology. 8:161–174, 1998.

    Article  Google Scholar 

  • Pliszka S. New developments in psychopharmacology of attention-deficit hyperactivity disorder. Expert Opin Investig Drugs. 10:1797–1807, 2001.

    Article  CAS  PubMed  Google Scholar 

  • Pliszka S, Lopez M, Crismon M, et al. A feasibility study of the children’s medication alorithm project CMAP algorithm for the treatment of ADHD. J Am Acad Child Adolesc Psychiatry. 42:279–287, 2003.

    Article  PubMed  Google Scholar 

  • Remschmidt H, Hennighausen K, Clement H, et al. Atypical neuroleptics in child and adolescent psychiatry. Eur Child Adolesc Psychiatry 9 Suppl:9–19, 2000.

    Article  Google Scholar 

  • Rey J, Sawyer M. Are psychostimulant drugs being used appropriately to treat child and adolescent disorders? Br J Psychiatry. 182:284–286, 2003.

    Article  PubMed  Google Scholar 

  • Ryan N, Bhatara V, Perel J. Mood stabilizers in children and adolescents. J Am Acad Child Adolesc Psychiatry. 38: 529–536, 1999.

    Article  CAS  PubMed  Google Scholar 

  • Safer D. Patterns of psychotropic medication prescribed by child psychiatrists in the 1990’s. J Child Adolesc. Psychopharmacology. 7:267–274, 1997.

    Article  CAS  Google Scholar 

  • Santosh P, Baird G. Psychopharmacotherapy in children and adults with intellectual disability. Lancet. 345:233–242, 1999.

    Article  Google Scholar 

  • Schulz F, Remschmidt H. Psychopharmacology of depressive states in childhood and adolescence. In I Goodyear ed. The Depressed Child and Adolescent. 2nd, ed. Cambridge University Press, Cambridge, 2001, pp 292–324.

    Chapter  Google Scholar 

  • Spencer T, Biederman J. Wilens T, et al. Novel treatments for attention/deficit/hyperactivity disorder in children. J Clin Psychiatry. 63 Suppl 12:16–22, 2002.

    CAS  PubMed  Google Scholar 

  • Steiner H, Sexena K. Chang K. Psychopharmacologic strategies for the treatment of aggression in juveniles. CNS Spectr. 8:298–308, 2003.

    PubMed  Google Scholar 

  • Tourbiu K. Strategies for pharmacology treatment of high functioning autism and Asperger syndrome. Child Adolesc Psychiatry Clin N Am. 12:23–45, 2003.

    Article  Google Scholar 

  • Varley C. Psychopharmacological treatment of major depressive disorder in children and adolescents. JAMA. 290: 1091–1093, 2003.

    Article  PubMed  Google Scholar 

  • Varley CK, Smith CJ. Anxiety disorders in the child and teen. Pediatr Clin North Am. 50:1107–1138, 2003.

    Article  PubMed  Google Scholar 

  • Vitiello B. Psychopharmacology for young children: clinical needs and research opportunities. Pediatrics. 108:983–989, 2001.

    Article  CAS  PubMed  Google Scholar 

  • Walkup J, Labellarte M, Riddle M et al. Treatment of pediatric anxiety disorders: an open-label extension of the research units on pediatric psychopharmacology anxiety study. J Child Adolesc Psychopharmacol. 12:175–188, 2002.

    Article  PubMed  Google Scholar 

  • Zito JM, Riddle MA. Psychiatric pharmacoepidemiology for children. Child Adoles. Psychiatric Clin North Am. 4:77–95, 1995.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Psychiatry, Dalhousie University Medical School, 5909 Veterans’ Memorial Lane 9th Floor, AJLB, Halifax, Nova Scotia, B3H 2E2, Canada

    Stan Kutcher MD (Prof.)

Authors
  1. Stan Kutcher MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Kinder- und Jugendpsychiatrie und -psychotherapie, Klinikum der Philipps-Universität Marburg, Hans-Sachs-Str. 4 und 6, 35033, Marburg, Germany

    Helmut Remschmidt

  2. Department of Social Medicine, Harvard Medical School, 641 Huntington Avenue, Boston, MA, 02115, USA

    Myron L. Belfer MD, MPH

  3. Douglas House Developmental Psychiatry, Cambridge University, 18b Trumpington Road, Cambridge, CB2 2AH, UK

    Ian Goodyer MD

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Kutcher, S. (2004). Medications. In: Remschmidt, H., Belfer, M.L., Goodyer, I. (eds) Facilitating Pathways. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18611-0_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-18611-0_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-62197-0

  • Online ISBN: 978-3-642-18611-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation